Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
33997919
PubMed Central
PMC8521581
DOI
10.1007/s00345-021-03715-4
PII: 10.1007/s00345-021-03715-4
Knihovny.cz E-zdroje
- Klíčová slova
- Biomarkers, Prostate cancer, SII, Salvage radical prostatectomy, Survival,
- MeSH
- brachyterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru imunologie mortalita patologie chirurgie MeSH
- lymfatické uzliny patologie MeSH
- lymfocyty * MeSH
- míra přežití MeSH
- multivariační analýza MeSH
- nádory prostaty imunologie mortalita patologie chirurgie MeSH
- neutrofily * MeSH
- počet leukocytů MeSH
- počet lymfocytů MeSH
- počet trombocytů MeSH
- předoperační období MeSH
- prognóza MeSH
- proporcionální rizikové modely MeSH
- prostatektomie * MeSH
- radioterapie s modulovanou intenzitou MeSH
- retrospektivní studie MeSH
- senioři MeSH
- staging nádorů MeSH
- trombocyty * MeSH
- záchranná terapie * MeSH
- zánět krev imunologie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: To examine the predictive and prognostic value of preoperative Systemic Immune-inflammation Index (SII) in patients with radio-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP). MATERIALS AND METHODS: This multicenter retrospective study included 214 patients with radio-recurrent PCa, treated with SRP between 2007 and 2015. SII was measured preoperatively (neutrophils × platelets/lymphocytes) and the cohort was stratified using optimal cut-off. Uni- and multivariable logistic and Cox regression analyses were performed to evaluate the predictive and prognostic value of SII as a preoperative biomarker. RESULTS: A total of 81 patients had high preoperative SII (≥ 730). On multivariable logistic regression modeling, high SII was predictive for lymph node metastases (OR 3.32, 95% CI 1.45-7.90, p = 0.005), and non-organ confined disease (OR 2.55, 95% CI 1.33-4.97, p = 0.005). In preoperative regression analysis, high preoperative SII was an independent prognostic factor for cancer-specific survival (CSS; HR 10.7, 95% CI 1.12-103, p = 0.039) and overall survival (OS; HR 8.57, 95% CI 2.70-27.2, p < 0.001). Similarly, in postoperative multivariable models, SII was associated with worse CSS (HR 22.11, 95% CI 1.23-398.12, p = 0.036) and OS (HR 5.98, 95% CI 1.67-21.44, p = 0.006). Notably, the addition of SII to preoperative reference models improved the C-index for the prognosis of CSS (89.5 vs. 80.5) and OS (85.1 vs 77.1). CONCLUSIONS: In radio-recurrent PCa patients, high SII was associated with adverse pathological features at SRP and survival after SRP. Preoperative SII could help identify patients who might benefit from novel imaging modalities, multimodal therapy or a closer posttreatment surveillance.
Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Federal Armed Services Hospital Koblenz Koblenz Germany
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Hospital Cologne Cologne Germany
Department of Urology University Hospital Zurich Zurich Switzerland
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran
Zobrazit více v PubMed
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al (2020) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 10.1016/j.eururo.2020.09.042 PubMed
Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER) Eur Urol. 2020 doi: 10.1016/j.eururo.2020.11.010. PubMed DOI PMC
Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–987. doi: 10.1016/j.eururo.2018.10.011. PubMed DOI
Walz J, Gallina A, Perrotte P, Jeldres C, Trinh QD, Hutterer GC, et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 2007;100(6):1254–1258. doi: 10.1111/j.1464-410X.2007.07130.x. PubMed DOI
Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol. 2009;5(10):1555–1584. doi: 10.2217/fon.09.121. PubMed DOI PMC
Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60(2):205–210. doi: 10.1016/j.eururo.2011.03.011. PubMed DOI PMC
Gontero P, Marra G, Alessio P, Filippini C, Oderda M, Munoz F, et al. Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches. J Urol. 2019;202(4):725–731. doi: 10.1097/JU.0000000000000327. PubMed DOI
Heidenreich A, Richter S, Thuer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol. 2010;57(3):437–443. doi: 10.1016/j.eururo.2009.02.041. PubMed DOI
Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int. 2020;20:499. doi: 10.1186/s12935-020-01590-4. PubMed DOI PMC
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi: 10.1038/nature07205. PubMed DOI
Vartolomei MD, D'Andrea D, Chade DC, Soria F, Kimura S, Foerster B, et al. Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urol Oncol. 2019;37(2):123–129. doi: 10.1016/j.urolonc.2018.11.013. PubMed DOI
Quhal F, Pradere B, Sari Motlagh R, Mori K, Laukhtina E, Aydh A, et al. Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva Urol Nefrol. 2020 doi: 10.23736/S0393-2249.20.03938-7. PubMed DOI
Roach M, 3rd, Hanks G, Thames H, Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–974. doi: 10.1016/j.ijrobp.2006.04.029. PubMed DOI
Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol. 2006;13(1):57–59. doi: 10.1097/01.pap.0000202017.78917.18. PubMed DOI
Shariat SF, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate. 2005;65(3):260–267. doi: 10.1002/pros.20242. PubMed DOI
Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol. 2004;171(3):1122–1127. doi: 10.1097/01.ju.0000113249.82533.28. PubMed DOI
Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007;67(6):614–622. doi: 10.1002/pros.20557. PubMed DOI
Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012;60(1):199–215. doi: 10.1111/j.1365-2559.2011.04033.x. PubMed DOI PMC
Jelonek K, Pietrowska M, Widlak P. Systemic effects of ionizing radiation at the proteome and metabolome levels in the blood of cancer patients treated with radiotherapy: the influence of inflammation and radiation toxicity. Int J Radiat Biol. 2017;93(7):683–696. doi: 10.1080/09553002.2017.1304590. PubMed DOI
McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. Mamm Genome. 2018;29(11–12):843–865. doi: 10.1007/s00335-018-9777-0. PubMed DOI PMC
Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D'Andrea D, Korn SM, Pones M, et al (2020) Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. Urol Oncol 38(6):600e9–e15. 10.1016/j.urolonc.2019.11.005 PubMed
Zhang JY, Ge P, Zhang PY, Zhao M, Ren L (2019) Role of neutrophil to lymphocyte ratio or platelet to lymphocyte ratio in prediction of bone metastasis of prostate cancer. Clin Lab 65(5). 10.7754/Clin.Lab.2018.181040 PubMed
Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20:224. doi: 10.1186/s12935-020-01308-6. PubMed DOI PMC
Rajwa P, Zyczkowski M, Paradysz A, Slabon-Turska M, Suliga K, Bujak K, et al. Novel hematological biomarkers predict survival in renal cell carcinoma patients treated with nephrectomy. Arch Med Sci. 2020;16(5):1062–1071. doi: 10.5114/aoms.2017.70250. PubMed DOI PMC
Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431–446. doi: 10.1038/nrc.2016.52. PubMed DOI
Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hamostaseologie. 2014;34(1):54–62. doi: 10.5482/HAMO-13-10-0054. PubMed DOI
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–5391. doi: 10.1158/0008-5472.CAN-08-3845. PubMed DOI PMC
Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004;100(11):2281–2291. doi: 10.1002/cncr.20270. PubMed DOI
Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front Pharmacol. 2016;7:376. doi: 10.3389/fphar.2016.00376. PubMed DOI PMC
Man YN, Chen YF. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel. Int Urol Nephrol. 2019;51(12):2189–2199. doi: 10.1007/s11255-019-02265-4. PubMed DOI
Fan L, Wang R, Chi C, Cai W, Zhang Y, Qian H, et al. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate. 2018;78(4):250–256. doi: 10.1002/pros.23465. PubMed DOI
Hu X, Shao YX, Yang ZQ, Dou WC, Xiong SC, Li X. Preoperative systemic immune-inflammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis. Cancer Cell Int. 2020;20:222. doi: 10.1186/s12935-020-01320-w. PubMed DOI PMC